Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly's tirzepatide is off FDA's shortage list
Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities Association (OFA), which called the FDA’s decision to remove tirzepatide from the shortage list a “reckless and arbitrary decision—lacking any semblance of lawful process.”
In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list
The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its shortage list.
Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list
GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. Senior Health Reporter Anjalee Khemlani reports more on the story and what it means for competitors,
Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage
The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of tirzepatide as it reconsiders whether the drug is in shortage.
Compounding pharmacies can make tirzepatide again
Click in for more news from The Hill{beacon} Health Care Health Care The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration
11h
on MSN
This is Huge News For Eli Lilly Investors
Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...
STAT
6d
As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
ConsumerAffairs
1d
Compounding pharmacies can keep making Mounjaro and Zepbound copies
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
1d
on MSN
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...
1d
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
3d
FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs
The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...
3d
Eli Lilly To Invest $364 Mln In UK's Biotech Segment To Tackle Health Challenges
Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...
Zacks.com on MSN
3h
Lilly Loses Around $14B This Week: How to Play LLY Stock
The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.
7d
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves
Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback